|
© 2009 American Academy of Neurology Incidence and prevalence of CIDP and the association of diabetes mellitusFrom the Department of Neurology (R.S.L., P.J.D., P.J.B.D.), Peripheral Neuropathy Research Laboratory (P.J.D., P.J.B.D.), Division of Epidemiology (L.J.M., C.L.), and Division of Biostatistics (J.R.), College of Medicine, Mayo Clinic, Rochester, MN. Address correspondence and reprint requests to Dr. P. James B. Dyck, Department of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905 dyck.pjames{at}mayo.edu. Background: The reported prevalence of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) varies greatly, from 1.9 to 7.7 per 100,000. CIDP is reported to occur more commonly in patients with diabetes mellitus (DM) but has not been rigorously tested. Objectives: To determine the incidence (1982–2001) and prevalence (on January 1, 2000) of CIDP in Olmsted County, Minnesota, and whether DM is more frequent in CIDP. Methods: CIDP was diagnosed by clinical criteria followed by review of electrophysiology. Cases were coded as definite, probable, or possible. DM was ascertained by clinical diagnosis or current American Diabetes Association glycemia criteria. Results: One thousand five hundred eighty-one medical records were reviewed, and 23 patients (10 women and 13 men) were identified as having CIDP (19 definite and 4 probable). The median age was 58 years (range 4–83 years), with a median disease duration at diagnosis of 10 months (range 2–64 months). The incidence of CIDP was 1.6/100,000/year. The prevalence was 8.9/100,000 persons on January 1, 2000. Only 1 of the 23 CIDP patients (4%) also had DM, whereas 14 of 115 age- and sex-matched controls (12%) had DM. Conclusions: 1) The incidence (1.6/100,000/year) and prevalence (8.9/100,000) of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are similar to or higher than previous estimates. 2) The incidence of CIDP is similar to that of acute inflammatory demyelinating polyradiculoneuropathy within the same population. 3) Diabetes mellitus (DM) is unlikely to be a major risk covariate for CIDP, but we cannot exclude a small effect. 4) The perceived association of DM with CIDP may be due to misclassification of other forms of diabetic neuropathies and excessive emphasis on electrophysiologic criteria.
Abbreviations: Az = azathioprine; AAN = American Academy of Neurology; AIDP = acute inflammatory demyelinating polyradiculoneuropathy; CB = conduction block; CI = confidence interval; CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; CMAP = compound muscle action potential amplitude; CV = conduction velocity; D = distal; DL = distal latency; DLRPN = diabetic lumbosacral radiculoplexus neuropathy; DM = diabetes mellitus; DPN = diabetic polyneuropathy; Dx = diagnosis; IVIg = IV immune globulin; LLM = lower limit of normal; MGUS = monoclonal gammopathy of undetermined significance; MM = mycophenolate mofetil; Mo = monophasic; Mtx = methotrexate; N = no; OR = odds ratio; P = proximal; Plex = plasma exchange; POEMS = plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes; Pr = progressive; Pred = prednisone; RR = relapsing–remitting; TD = temporal dispersion; Y = yes.
Supported in part by a grant from the National Institute of Neurological Disorders and Stroke (NS 36797) and the Rochester Epidemiology Project (AR 30582). Disclosure: The authors report no disclosures. Received December 23, 2008. Accepted in final form March 31, 2009. This article has been cited by other articles:
|
||||||||||||
